These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19062123)

  • 1. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
    Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
    Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
    Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
    Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
    Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
    Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
    Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
    Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
    Nakamura T; Fujiwara N; Sato E; Ueda Y; Sugaya T; Koide H
    Kidney Blood Press Res; 2010; 33(3):213-20. PubMed ID: 20588058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
    Daikuhara H; Fukunaga K; Ohshima T
    Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
    Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
    Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
    Li L; Zhou N; Gong H; Wu J; Lin L; Komuro I; Ge J; Zou Y
    Hypertens Res; 2010 Dec; 33(12):1289-97. PubMed ID: 20944638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
    J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
    Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril.
    Ko GT; Tsang CC; Chan HC
    Adv Ther; 2005; 22(2):155-62. PubMed ID: 16020405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Ichikawa Y
    Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiology patient page. Angiotensin receptor blockers.
    Terra SG
    Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
    [No Abstract]   [Full Text] [Related]  

  • 20. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
    Sharma AM; Davidson J; Koval S; Lacourcière Y
    Cardiovasc Diabetol; 2007 Oct; 6():28. PubMed ID: 17910747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.